Nasopharyngeal carcinoma (NPC) is a malignant epithelial tumor originating in the
nasopharynx and has a high incidence in Southeast Asia and North Africa. To develop these …

Nasopharyngeal carcinoma is a rare disease in Western countries. Nevertheless, its
incidence in China, Singapore, and other Eastern countries reaches 20 cases per 100,000 …

Nasopharyngeal carcinoma (NPC) is a specific entity different from head and neck
carcinoma. Incidence is higher in South-East Asia and North Africa. Prognosis, especially for …

Background Patients with locoregionally advanced nasopharyngeal carcinoma have a high
risk of disease relapse, despite a high proportion of patients attaining complete clinical …

Background Platinum-based doublet chemotherapy regimens, preferentially gemcitabine
plus cisplatin, are generally considered the first-line standard of care for patients with …

Importance Induction or adjuvant chemotherapy with concurrent chemoradiotherapy (CCRT)
are first-line treatment options for treatment of locoregionally advanced nasopharyngeal …

Background and objective No randomized trial has been reported comparing different
chemotherapy regimens on disseminated nasopharyngeal carcinoma (NPC). This study …

Background: The majority of published studies in recurrent or metastatic nasopharyngeal
carcinoma (RM-NPC) are single-arm trials. Reliable modelling of progression-free survival …

Importance of the field: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the
mainstay of treatment for several solid tumors, including colorectal, breast and head and …

Opinion statement Nasopharyngeal carcinoma (NPC) is distinct in its anatomic location and
biology from other epithelial head and neck cancer (HNC). There are 3 WHO subtypes …